Affiliations 

  • 1 Department of Neurology and Psychiatry, University of Santo Tomas, Manila, Philippines
  • 2 Ipsen, Singapore, Singapore
  • 3 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 4 Division of Neurology, University of Malaya Medical Centre, Kuala Lumpur, Malaysia
  • 5 Hospital Kuala Lumpur, Kuala Lumpur, Malaysia
  • 6 Tan Tock Seng Hospital, Singapore, Singapore
  • 7 Singapore General Hospital, Singapore, Singapore
  • 8 China Medical University Hospital, Taichung, Taiwan
  • 9 Perpetual Succor Hospital, Cebu City, Philippines
  • 10 Ipsen, Ho Chi Minh City, Vietnam
  • 11 Ipsen, Boulogne-Billancourt, France
  • 12 Tung Wah Hospital, Hong Kong, Hong Kong SAR, China
  • 13 Department of Rehabilitation Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Front Neurol, 2024;15:1335365.
PMID: 38651107 DOI: 10.3389/fneur.2024.1335365

Abstract

PURPOSE: Describe real-life practice and outcomes in the management of post-stroke upper limb spasticity with botulinum toxin A (BoNT-A) in Asian settings.

METHODS: Subgroup analysis of a prospective, observational study (NCT01020500) of adult patients (≥18 years) with post-stroke upper limb spasticity presenting for routine spasticity management, including treatment with BoNT-A. The primary outcome was goal attainment as assessed using goal-attainment scaling (GAS). Patients baseline clinical characteristics and BoNT-A injection parameters are also described.

RESULTS: Overall, 51 patients from Asia were enrolled. Rates of comorbid cognitive and emotional problems were relatively low. Patients tended to have more severe distal limb spasticity and to prioritize active over passive function goals. Most (94.1%) patients in the subgroup were treated with abobotulinumtoxinA. For these patients, the median total dose was 500 units, and the most frequently injected muscles were the biceps brachii (83.3%), flexor carpi radialis (72.9%), and flexor digitorum profundus (66.7%). Overall, 74.5% achieved their primary goal and the mean GAS T score after one treatment cycle was 56.0 ± 13.0, with a change from baseline of 20.9 ± 14.3 (p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.